Gracell Biotechnologies (GRCL) Stock Price: Why It Increased Over 15% Today

By Amit Chowdhry ● Jun 3, 2022
  • The stock price of Gracell Biotechnologies Inc (NASDAQ: GRCL) increased by over 15% during intraday trading today. This is why.

The stock price of Gracell Biotechnologies Inc (NASDAQ: GRCL) – a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer – increased by over 15% during intraday trading today. Investors are responding positively to Gracell Biotechnologies announcing that the company plans to hold a clinical update call on June 13 after the European Hematology Association 2022 Hybrid Congress (EHA 2022) as the data is subject to meeting’s embargo policy until June 12.

The management team intends to highlight clinical data from 3 investigator-initiated trials (IIT) for its BCMA/CD19 dual-targeting FasTCAR-T candidate GC012F and allogeneic TruUCAR-T candidate GC502 that will be presented at 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting and EHA 2022 as follows:

— Updated clinical data from a multicenter IIT evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in oral abstract presentations on June 5 at ASCO 2022 and on June 12 at EHA 2022

— Initial clinical data from an ongoing IIT evaluating GC012F for the treatment of relapsed/refractory B-NHL in a poster presentation on June 10 at EHA 2022

— Updated data with longer follow-up of GC502 in relapsed/refractory B-ALL in a poster presentation on June 10 at EHA 2022

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.